Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “INFUSIONS”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 109 records · Page 6Linked to original sources
PubMed1989

Potency of infused spinal antinociceptive agents is inversely related to magnitude of tolerance after continuous infusion.

By employing a constant-rate (1 microliter/hr) constant-dose intrathecal infusion pump in rats, groups received a 7-day infusion of one of three concentrations (in nmol/hr) of each of the following receptor preferring ligands: morphine (mu: 2, 6, 20), sufentanil (mu: 0.06, 0.2, 0.6), DAMGO (mu: 0.1, 0.3, 1.0), DADLE (delta: 2, 6, 20) or ST-91 (alpha-2: 3, 10, 30). On day 7 the magnitude of tolerance was assessed by establishing i.t. dose-response curves for the effect of the chronic drug given as a bolus. Each infused animal was used for one bolus injection. It was observed that for all drugs, a parallel rightward shift in the dose-response curve was produced with the degree of shift proportional to the log of the infusion dose. Of particular significance was the finding that drugs differed significantly in the magnitude of the shift produced by the chronic infusion of equieffective concentrations. Thus, at the intermediate infusion dose, the degree of the shift in the bolus dose-response curve (i.e., magnitude of tolerance) for morphine, DADLE, ST-91, DAMGO and sufentanil was 55, 46, 29, 7 and 2, respectively. These data are interpreted to suggest that agents with high potency and a significant receptor reserve will produce a smaller shift in the dose-response curve (e.g., sufentanil and DAMGO) than the similar infusion of an equieffective dose of another agent with less potency and a smaller population of spare receptors (morphine).

Analgesics↗
PubMed1986

[Consecutive intra-arterial infusion of cis-diamminedichloroplatinum with continuous intra-arterial infusion of 5-fluorouracil in locally advanced ovarian cancer].

Consecutive intraarterial infusion of cis-diamminedichloroplatinum (CDDP) with continuous intraarterial infusion of 5-fluorouracil (5-FU) (250 mg/day) was administered to 10 patients with locally advanced (peritonitis carcinomatosa) ovarian cancer. The dose of CDDP was 10 mg/5 min/body/day and it was administered for about 10-20 consecutive days per one course. Each course was repeated at about 3-week intervals. The main dose-limiting factor was the number of peripheral leucocytes. The results were 6 PR, 1 MR and 2 NC out of 9 evaluable cases, all of whom had had previous therapy. The antitumor effect needed over 200 mg of intraarterial CDDP and the response lasted from 2 to more than 9 months. Among 6 patients who obtained PR, 4 had failed to respond to intravenous or intraperitoneal infusion of CDDP, which suggested that a high concentration and a critical drug gradient across the tumor cell membrane were more essential for a significant tumor cell kill, with CDDP, than the time of exposure. The toxic effects of intraarterial infusion of CDDP were almost absent as compared with those of intravenous infusion, which consisted of nausea and vomiting. Renal dysfunction was also mild. Other toxic effects were not different from those observed in intravenous infusion. Our results with intraarterial infusion of CDDP clearly indicate that this approach can deliver a high therapeutic efficacy in patients with advanced ovarian cancer with markedly less toxic effects.

Adolescent↗
PubMed1983

[Experimental studies on the optimal therapeutic mode of intra-arterial infusion of 5-fluorouracil. (1) Preparation of an animal model for continuous intra-arterial infusion and comparison of the therapeutic and adverse effects of 5-fluorouracil delivered by various modes].

5-Fluorouracil (5-FU) is one of the most popular anticancer drugs, especially in treatment of for adenocarcinoma; however, an optimal therapeutic schedule of 5-FU is not determined even now. An animal model for continuous intraarterial infusion in rats was constructed using retrograde cannulation to aorta via right femoral artery in order to study the intraarterial and systemic effects of 5-FU on Yoshida sarcoma implanted in left fore limb and hind limb subcutaneously. By implanting Yoshida sarcoma in fore and hind limb and cannulating and infusing aorta, the regional and systemic antitumor effects could be compared in the same animal. Antitumor effect and toxicity after intraarterial 5-FU administration was studied at various infusion time and doses. The results revealed that intraarterial infusion of 5-FU was more effective than its systemic administration from view points of the antitumor effect. The antitumor effect after one shot intraarterial injection of 5-FU was ar superior to that after continuous infusion of 5-FU. However, toxicity after one shot injection was much more severe than continuous infusion. Consequently, the desirable administration schedule of 5-FU appears to be an intraarterial infusion as short time as possible within tolerable toxicity.

Animals↗
PubMed1994

Pharmacokinetics of high-dose VP-16: 6-hour infusion versus 34-hour infusion.

VP-16 was administered in high doses (30-45 mg/kg) in combination with busulfan (BU) and cyclophosphamide (CY). The anticancer activity of VP-16 is thought to be schedule-dependent. We investigated a 6-h and a 34-h infusion of VP-16 to compare pharmacokinetic parameters and toxicity. Blood samples were taken from a total of 16 patients during infusion time (6 h and 34 h, respectively) and thereafter up to 2 days after bone marrow transplantation (BMT). VP-16 concentrations were measured in all plasma samples with HPLC technique and electrochemical detection and the results were analyzed with a pharmacokinetic data analysis system. All calculated pharmacokinetic parameters in the two patient groups were essentially similar. There were no statistically significant differences in half-lives, mean residence time, volume of distribution, total clearance and area under the curve. The treatment-related toxicity was not different between groups. The major difference was the maximal concentration in the case of 6-h infusions (122 +/- 35 micrograms/ml) and in the case of 34-h infusions (23.2 +/- 4.9 micrograms/ml) and the duration of VP-16 concentrations with > 10 and > 1 microgram/ml. Drug levels above these thresholds were always longer in case of 34-h infusions. In 8 of 16 patients VP-16 concentrations were measured in plasma samples at the time of BMT ranging from 80 to 820 ng/ml. The two different schedules for VP-16 administration, either given as a 6-h infusion or as a 34-h infusion, are bioequivalent in pharmacokinetic terms.(ABSTRACT TRUNCATED AT 250 WORDS)

Acute Disease↗
PubMed1998

Effect of infusion of hypertonic saline solution of conscious heifers with hypoxemia caused by endotoxin infusion.

OBJECTIVE: To compare effects of i.v. infusion of a small volume (5 ml/kg of body weight) of hypertonic saline (7.2% NaCl) solution (HSS) and i.v. infusion of an equivalent volume of isotonic saline (0.9% NaCl) solution (ISS) on arterial blood gases in conscious heifers with hypoxemia caused by endotoxin infusion. ANIMALS: 9 Holstein heifers. PROCEDURE: All heifers received 2.0 microg of endotoxin/kg, i.v., during a 5-minute period. Twenty-five minutes after endotoxin infusion, 3 heifers received ISS, 3 received HSS, and the remaining 3 did not receive fluids (control). Heifers were monitored for 150 minutes after initiation of fluid replacement. Arterial blood gases, blood pressure, and serum electrolyte concentrations were measured. RESULTS: Endotoxin administration had a profound effect on pulmonary function, causing severe hypoxemia accompanied by a significant decrease in the partial pressure of oxygen (PaO2) and a significant increase in the arterial-alveolar O2 gradient (P[A-a]O2). Cattle in the HSS group had progressive and significant increases in PaO2 and O2 saturation, compared with the other groups. The P(A-a)O2 values for the control and ISS groups were slightly decreased until 150 minutes after initiation of fluid replacement; however, HSS infusion induced a progressive and significant decrease in P(A-a)O2 for the remainder of the experimental period. CONCLUSIONS AND CLINICAL RELEVANCE: Rapid infusion of HSS can successfully resuscitate conscious cattle with induced pulmonary dysfunction. Infusion of HSS may be beneficial for initial resuscitation of cattle with naturally developing bovine respiratory disease complex.

Animals↗
PubMed1987

Intermittent infusion of progesterone potentiates whereas continuous infusion reduces amphetamine-stimulated dopamine release from ovariectomized estrogen-primed rat striatal fragments superfused in vitro.

In the present experiment we examined the effect of a direct in vitro infusion of progesterone upon spontaneous and amphetamine-stimulated in vitro dopamine (DA) release and post-superfusion DA tissue concentration of corpus striatum tissue fragments from ovariectomized and estrogen-treated female rats. An intermittent infusion of progesterone at a dose of 2 ng/ml produced a significant increase in amphetamine-stimulated DA release and post-superfusion DA tissue concentration compared to similar superfusions infused with medium alone or cholesterol (2 ng/ml). Higher (50 ng/ml) or lower (0.2 ng/ml) doses of progesterone were ineffective and a continuous infusion of progesterone at an identical total concentration to that of the intermittent 2 ng/ml dose inhibited both amphetamine-stimulated DA release and post-superfusion DA tissue concentration. With the exception of 5 alpha DHP (dihydroxyprogesterone) intermittent infusions of various metabolites, a synthetic progestin (R5020) at 2 ng/ml and estradiol at both 0.2 ng/ml and 2 ng/ml failed to modify significantly the amphetamine-stimulated DA response. However, pregnanolone, 5 alpha DHP, R5020 at 2 ng/ml and estradiol at 0.2 ng/ml increased post-superfusion DA tissue concentration to levels comparable to that of progesterone. These results demonstrate that in vitro progesterone can directly alter the amphetamine-stimulated DA release from dopaminergic terminals of corpus striatal tissue fragments. This effect appears quite specific for progesterone as well as for a specific dose and mode of infusion of this gonadal steroid. Moreover, progesterone can exert opposite effects upon the amphetamine-evoked DA release from the corpus striatum as a function of its mode of infusion suggesting a means by which one hormone can differentially alter central nervous system function.

Animals↗
PubMed2005

Hippocampal infusions of pyruvate reverse the memory-impairing effects of septal muscimol infusions.

Hippocampal infusions of glucose reverse memory deficits in spontaneous alternation and in a continuous multiple trial inhibitory avoidance task. The current experiments tested whether glucose metabolism may participate in these effects of glucose. Specifically, these experiments determined whether the glycolytic metabolite pyruvate would mimic these effects of glucose. Male Sprague-Dawley rats were given septal infusions of vehicle or the gamma-aminobutyric acid (GABA) receptor agonist muscimol (0.15 nmol for spontaneous alternation or 5 nmol for continuous multiple trial inhibitory avoidance) combined with hippocampal infusions of vehicle or pyruvate (200 nmol) 15 min prior to assessing spontaneous alternation or training in a continuous multiple trial inhibitory avoidance task. The infusions of muscimol decreased percent alternation scores and continuous multiple trial inhibitory avoidance retention latencies tested 48 h after training. More importantly, hippocampal infusions of pyruvate reversed the deficits produced by septal infusions of muscimol on both tasks. These findings show for the first time that hippocampal infusions of pyruvate influence memory and suggest that glucose may affect memory via glycolytic metabolism.

Animals↗
PubMed2001

Infusions of physostigmine into the hippocampus or the entorhinal cortex attenuate avoidance retention deficits produced by intra-septal infusions of the GABA agonist muscimol.

Septal gamma-aminobutyric acid (GABA) receptor activation is known to disrupt memory formation, although the mechanisms underlying this impairment remain unclear. The present study explored the possibility that high levels of septal GABA receptor activity might impair memory by down-regulating acetylcholine (ACh) function in archicortex and entorhinal cortex. To test this possibility, rats were trained on an avoidance task 15 min after receiving intra-septal infusions of vehicle or muscimol (5 nmol/0.5 microl) combined with unilateral intra-hippocampal (10 microl/1 microl) or intra-entorhinal cortex (1.875 microg/0.25 microl) infusions of vehicle or the acetylcholinesterase inhibitor physostigmine. We demonstrate that these infusions do not alter acquisition performance on a continuous multiple trial inhibitory avoidance task. However, intra-septal infusions of muscimol dramatically impair retention performance 48 h later. More importantly, infusions of physostigmine into the hippocampus or the entorhinal cortex, at doses that do not influence acquisition or retention performance when infused alone, attenuate the impairing effects of the muscimol infusions on retention. We suggest that high levels of septal GABA receptor activity might impair memory by down-regulating ACh levels in the hippocampal region, and that such memory impairments can be ameliorated by increasing ACh levels in the hippocampus or entorhinal cortex.

Animals↗
PubMed1996

Experimental infusion phlebitis: importance of titratable acidity on phlebitic potential of infusion solution.

The titratable acidity of infusion solutions has never been taken into account in infusion phlebitis. This study aims to clarify the importance of titratable acidity on the phlebitic potential of infusion solutions. Solutions with different titratable acidity (from 0.16 to 12 mEq/L) were infused into the ear veins of 6 rabbits for 6 h at 10 mL/kg/h, and the veins were later examined histopathologically. Even at pH 4.0, a commercial 10% glucose solution scarcely caused any changes because of its very low titratable acidity (0.16 mEq/L). A 10% glucose solution with its titratable acidity adjusted to 3 mEq/L (pH 4.3) with citrate and NaOH, however, caused phlebitic changes in all 6 rabbits, and adjusting the titratable acidity to 12 mEq/L (pH 4.4) increased the degree of phlebitis. On the other hand, a 10% glucose solution with a pH of 5.4 and a titratable acidity of 6 mEq/L caused slight phlebitic changes in half the rabbits. These results suggest that 1) the titratable acidity of infusion solutions is important to the phlebitic potential when the pH is low, 2) when the pHs are similar, the phlebitic potential of infusion solutions depend on the titratable acidity, and 3) the phlebitic potential of infusion solutions can not be estimated by pH or titratable acidity alone.

Journal Article↗
PubMed1980

Protection of the ischemic myocardium calcium-free cardioplegic infusates and the additive effects of coronary infusion and ischemia in the induction of the calcium paradox.

Studies in the globally ischemic, isolated rat heart have shown that the preischemic coronary infusion of calcium-free cardioplegic solution may lead to an exacerbation of the postischemic leakage of creatine kinase. This exacerbation could be prevented by the inclusion of trace amounts of calcium in the coronary infusate or could be postponed by the omission of calcium during postischemic reperfusion. The calcium paradox, observed with such a combination of coronary infusion and ischemia required for its induction a less extensive cellular calcium depletion than that induced by infusion only and was the result of 2 additive factors: the washout of tissue calcium during preischemic infusion and the cellular influx of residual membrane-bound calcium during ischemia. The balance between protective and damaging properties with calcium-free cardioplegic infusates was influenced by the concentration of Na+, K+, Mg++ and procaine in the infusates as these agents influence patterns of calcium redistribution.

Animals↗
PubMedDate not supplied

Alternate day infusion of calcium and phosphate in very low birth weight infants: wasting of the infused mineral.

Very low birth weight infants require greater intakes of calcium and phosphate than can be supplied simultaneously in parenteral nutrition. We investigated the biochemical effects and retention of calcium and phosphate when each was administered for 24 h on an alternate day schedule as part of total parenteral nutrition. Serum and urine were collected during a 24 h basal period and during randomly ordered 24 h infusions of either calcium or phosphate in 14 infants during the first week of life. In general, the urinary excretion of the infused mineral (calcium or phosphorus) increased during the 24 h period of its infusion. The serum phosphorus level fluctuated widely from day to day while the serum calcium level did not change. During the 24 h infusion of phosphate, phosphate retention was 67.9 +/- 7.4% and, during the 24 h infusion of calcium, calcium retention was 72.5 +/- 4.3%. However, ongoing excretion of each mineral on the day it was not infused meant that 48.3% of the 48 h phosphate intake and 42.2% of the 48 h calcium intake were lost in the urine. We conclude that excessive amounts of the administered mineral were excreted and that alternate day infusion of calcium and phosphate is an unsatisfactory method for providing these minerals. Attainment of sufficient retentions of calcium and phosphate will require development of novel methods of simultaneous administration which provide calcium and phosphate in high concentrations.

Calcium↗
PubMed2003

New infusion cannula for prevention of retinal damage by infusion air during vitrectomy.

PURPOSE: Postoperative visual field defects are sometimes found after macular hole surgery. We have previously shown that damage to the retina by air infusion from an infusion cannula is a causative factor. To minimize such damage, we modified the infusion cannula and examined its effects experimentally. METHODS: An infusion cannula with a closed tip and openings on four sides was created. Experimentally, a vitrectomy was performed in rabbit eyes using this new infusion cannula or a conventional cannula. After fluid-air exchange at an air pressure of 40 mmHg, eyes were removed and processed for histologic examination. The areas of the retinal damage caused by air infusion were evaluated. RESULTS: The area of retinal damage created by the new cannula was reduced significantly when compared with damage from conventional cannula use. CONCLUSION: This new cannula, designed for the purpose of scattering the air infusion, can reduce retinal damage, which leads to less frequent postoperative visual field defects.

Air↗
PubMed1979

Glucose infusion potentiates the acute insulin response to nonglucose stimuli during the infusion of somatostatin.

These studies assessed the ability of glucose infusions to potentiate the acute insulin response (AIR) to iv isoproterenol (12 micrograms), arginine (750 mg), or glucose (5 g) that was previously inhibited by an infusion of somatostatin (SRIF). SRIF (1.7 micrograms/min) markedly inhibited the AIR to isoproterenol (AIR before SRIF, 28 +/- 1 microU/ml; AIR during SRIF, 8 +/- microU/ml; P less than 0.025), arginine (AIR before SRIF, 6 +/- 2 microU/ml; AIR during SRIF, 1 +/- 1 microU/ml; P less than 0.01), and glucose (AIR before SRIF, 19 +/- 7 microU/ml; AIR during SRIF, 1 +/- microU/ml; P less than 0.05). The administration of a glucose infusion of 105 mg/min partially restored the AIR to isoproterenol and arginine. Glucose infused at 440 mg/min fully restored the AIR to both isoproterenol (AIR during SRIF plus glucose, 31 +/- 4 microU/ml) and arginine (AIR during SRIF plus glucose, 9 +/- 2 microU/ml). In contrast, the AIR to glucose was not affected by infusion of glucose (AIR during SRIF plus glucose, 0 +/- 1 microU/ml). In the absence of SRIF, glucose infusion potentiates the AIR to isoproterenol and arginine but not to glucose. Therefore, during SRIF infusion, glucose retains the ability to potentiate the AIR to nonglucose stimuli despite the loss of the ability to stimulate insulin release directly. These data suggest that the potentiating effects of glucose and the inhibiting effects of SRIF may be mediated by a common mechanism affecting insulin release.

Animals↗
PubMed1999

Effect of glucose supply on fasting nitrogen excretion and effect of level and type of volatile fatty acid infusion on response to protein infusion in cattle.

Two experiments were carried out on cattle nourished entirely by intragastric infusion, to determine the extent to which glucose or a glucose precursor determines the response to protein infusion in energy-undernourished animals. In order to determine the requirement for glucose in 1-year-old fasting cattle, glucose was infused at increments to supply 0, 1.5, 2.5, 3.5, 4.5, 5.5 and 6.5 g/kg metabolic body weight (W0.75) and the effects on plasma beta-hydroxybutyrate and N excretion were measured. At 5.5 g glucose/kg W0.75 plasma beta-hydroxybutyrate was reduced to a basal level of 1.65 mmol/l and fasting N excretion reduced from 529 to 280 mg N/kg W0.75. No further reduction was observed with the higher level of 6.5 g glucose/kg W0.75. In the second trial, three steers were used in a 3 x 3 Latin square design and infused with a volatile fatty acid mixture of 65, 27 and 8 mol acetic, propionic and butyric acids respectively/100 mol, either at an estimated maintenance energy level of 450 kJ/kg W0.75 and supplying a calculated glucose equivalent level of 13.0 g/kg W0.75 (M1A), or at 1.5 x maintenance supplying a glucose equivalent of 20 g/kg W0.75 (M1.5A). Another mixture infused at the maintenance energy level contained 49, 43 and 8 mol acetic, propionic and butyric acids respectively/100 mol but with a glucose equivalent of 20 g/kg W0.75 (M1P). Casein was infused at each of these energy treatments to supply 0, 200, 400, 800, 1600 and 2500 mg N/kg W0.75 daily, and N balance and blood metabolites were measured. N retention increased linearly (r 0.98) with casein infusion. The coefficients for N retention were 0.55, 0.57 and 0.64 for M1A, M1.5A and M1P respectively. The mean efficiency of N utilization was 0.58. The results suggest that provided the glucose need is met there is no relationship between energy supply and efficiency and level of protein retention. However, the results also indicate that glucose requirement in cattle may be higher than that previously observed in sheep.

Acetic Acid↗
PubMed1991

Continuous local intra-arterial infusion of antithrombotic agents for replantation (comparison with intravenous infusion).

The success rate of replantation of amputated digits and limbs appears to be improved by local continuous intra-arterial infusion of urokinases, heparin and PGE1 at a daily dose of 240,000 I.U., 10,000 U, and 40 micrograms, respectively, for ten days, in comparison to intravenous infusion of the drugs. The purpose of this study was to investigate the difference between the haematological effects of intra-arterial and intravenous infusion. Accordingly coagulation and fibrinolytic enzyme levels were examined before, and at 4 and 12 hours after the start of infusion and on the 3rd and 10th postoperative days. Intra-arterial infusion was advantageous over intravenous infusion probably because the effect of general metabolism on drug levels was small, drugs exhibited immediate action and efficacy was localised. No particular side effects were demonstrated.

Blood Coagulation Factors↗
PubMed1998

Evaluation of recombinant factor VIII (Kogenate) stability for continuous infusion using a minipump infusion device.

Continuous infusion of recombinant factor VIII (rFVIII) is desirable in clinical settings in order to maintain haemostatic levels in a cost-effective manner. This study was designed to determine rFVIII stability over time using a minipump set-up, which has been employed by clinicians for continuous infusion of rFVIII. Vials from three lots of Kogenate (Bayer Corporation) were reconstituted in sterile water for injection, pooled and transferred to minipump infusion sets composed of either polyvinylchloride (Medex # IPR86/tube volume 0.5 mL) or polyethylene (McGraw S5904-52, tube and adapter volume 2.1 mL), and held in temperature-controlled rooms at 5 degrees C, 25 degrees C and 30 degrees C. Additional bags of rFVII were prepared with heparin (4 U mL-1), and maintained at 30 degrees C. rFVIII was infused at a rate of 1.0 mL h-1. Samples were analysed for rFVIII activity over a 7-day period at 0, 1, 15, 24, 78 and 168 h. Prior to the start of the timed study, rFVIII activity was measured in the lot pools and in the polyvinylchloride or polyethylene bags, and in the first flush volumes through the tubing. There was no difference in rFVIII activity measured in the pools compared to the bags. rFVIII levels in the initial 3-mL infusion through the tubing showed a slight decrease in activity compared to the initial level which amounted to an insignificant loss of activity for the polyvinylchloride tubing but a significant loss in the polyethylene tubing (approximately 10 IU absolute loss in polyvinylchloride vs. 100 IU loss in polyethylene). After an initial flush of 1.0 mL for polyvinylchloride and 5.0 mL for polyethylene, activity returned to baseline and subsequently remained stable for all time points and temperatures from 5-30 degrees C over the 7-day period. We conclude that the standard polyvinylchloride in polyethylene minipump bags and tubing provide excellent delivery and stability of rFVIII for continuous infusion with or without heparin, and can be used in hospital and ambulatory settings.

Drug Evaluation↗
PubMed1993

Effect of intravenous infusion of ranitidine on intragastric acidity in fasting subjects: comparison with bolus or Gastrojet (pH-stat-adjusted) infusion.

This study was undertaken in nine fasting healthy volunteers to compare the effect of intravenous continuous infusion versus bolus injection of ranitidine on 12-h intragastric pH, and to compare the efficacy of these two modes of administration of pH-stat-adjusted infusion of ranitidine using the Gastrojet. Each volunteer had three study sessions with 12-h pH measurements. In the ranitidine infusion treatment arm (RAN-INF), ranitidine was continually infused intravenously using an IVAC-pump at a dose of 0.125 mg mg.kg over a 12-h period. In the ranitidine bolus treatment arm (RAN-BOL), ranitidine bolus 50 mg was given over 10 min, every 6 h. When ranitidine infusion was given by the pH stat method using the Gastrojet (RAN-JET), sufficient ranitidine was given to maintain a present value of pH > or = 5. The study was analysed with a 3 x 3 Latin square cross-over design with multiple measurements of each phase of the cross-over. No difference was found between RAN-INF and RAN-BOL in 12-h or in daytime (10.00-18.00 h) mean pH, median pH, or percentage of pH > or = 5. Using RAN-JET, 89.5% of the pH values were > or = 5., compared with 39.7% and 40.0% with RAN-INF or RAN-BOL. RAN-JET also gave higher (P < 0.05) mean and median 12-h or daytime pH values, as compared with RAN-INF or RAN-BOL. The mean doses of ranitidine given in the 12-h infusion periods were 100 mg, 109 mg and 112 mg (RAN-BOL, RAN-INF and RAN-JET, respectively). Thus, this superior inhibition of acid inhibition achieved with Gastrojet does not require higher mean doses of ranitidine. These findings cannot necessarily be applied to persons with duodenal ulcer disease or to patients in an intensive-care unit setting. However, the data do raise the possibility that much greater inhibition of acid inhibition can be achieved by individualizing the dose of ranitidine using the Gastrojet.

Adult↗
PubMed1980

Intraarterial infusion chemotherapy for hepatic carcinoma using a totally implantable infusion pump.

Intraarterial infusion chemotherapy has several theoretical advantage over conventional therapy for the treatment of unresectable malignancies. However, the catheter problems and patient restriction to the hospital associated with its use have resulted in infrequent application and a notable lack of progress in this field of oncology. This paper describes the use of a totally implantable, percutaneously refillable infusion pump in 5 patients with primary or metastatic carcinoma of the liver. The infusion cannulae were placed into the hepatic arteries under direct vision at laparotomy, and the pumps were placed in subcutaneous pockets. Four patients received infusions of 5-fluorodeoxyuridine at rates of 0.2-0.5 mg/kg/day for periods of three to 29 weeks; the pump in the fifth patient was defective and was removed. The implanted pumps were well tolerated in these subjects, who received chemotherapy as outpatients; the only adverse effects noted were related to FUDR toxicity. This implantable infusion pump appears to be a practical means of delivering long-term intraarterial infusion chemotherapy to outpatients.

Antineoplastic Agents↗